Table of Contents

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

 

FORM 10-Q

 

 

(Mark One)

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2012

OR

 

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from            to            

Commission File Number 0-6533

 

 

ALSERES PHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in Its Charter)

 

 

 

Delaware   87-0277826

(State or Other Jurisdiction of

Incorporation or Organization)

  (IRS Employer
Identification No.)
239 South Street, Hopkinton, Massachusetts   01748
(Address of Principal Executive Offices)   (Zip Code)

(508) 497-2360

(Registrant’s Telephone Number, Including Area Code)

None

(Former Name, Former Address and Former Fiscal Year, if Changed Since Last Report)

 

 

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes   x     No   ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes   x     No   ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

 

Large accelerated filer   ¨    Accelerated filer   ¨
Non-accelerated filer   ¨   (Do not check if a smaller reporting company)    Smaller reporting company   x

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes   ¨     No   x

As of October 31, 2012, there were 30,635,720 shares of the registrant’s Common Stock issued and outstanding.

 

 

 

Table of Contents

ALSERES PHARMACEUTICALS, INC.

FORM 10-Q

TABLE OF CONTENTS

 

     Page  

Part I FINANCIAL INFORMATION

  

Item 1 Financial Statements (Unaudited)

  

Condensed Consolidated Balance Sheets as of September 30, 2012 and December 31, 2011

     3   

Condensed Consolidated Statements of Comprehensive Loss for the three and nine months ended September 30, 2012 and 2011, and for the period from inception (October 16, 1992) to September 30, 2012

     4   

Condensed Consolidated Statements of Cash Flows for the nine months ended September  30, 2012 and 2011, and for the period from inception (October 16, 1992) to September 30, 2012

     5   

Notes to Condensed Consolidated Financial Statements

     7   

Item  2 Management’s Discussion and Analysis of Financial Condition and Results of Operations

     14   

Item 3 Quantitative and Qualitative Disclosures About Market Risk

     19   

Item 4 Controls and Procedures

     19   

Part II OTHER INFORMATION

     20   

Item 1 Legal Proceedings

     20   

Item 6 Exhibits

     20   

SIGNATURES

     21   

EX-31.1

  

EX-31.2

  

EX-32.1

  

EX-32.2

  

EX-101 INSTANCE DOCUMENT

  

EX-101 SCHEMA DOCUMENT

  

EX-101 CALCULATION LINKBASE DOCUMENT

  

EX-101 LABELS LINKBASE DOCUMENT

  

EX-101 PRESENTATION LINKBASE DOCUMENT

  

EX-101 DEFINITION LINKBASE DOCUMENT

  

In this report, “we”, “us”, and “our” refer to Alseres Pharmaceuticals, Inc. The following are trademarks of ours that are mentioned in this Quarterly Report on Form 10-Q: Alseres™ and Altropane ® . All other trade names, trademarks or service marks appearing in this Quarterly Report on Form 10-Q are the property of their respective owners and are not the property of Alseres Pharmaceuticals, Inc. or any of our subsidiaries.

 

2

Table of Contents

Part I — FINANCIAL INFORMATION

Item 1 — Financial Statements

Alseres Pharmaceuticals, Inc.

(A Development Stage Company)

Condensed Consolidated Balance Sheets

 

     (Unaudited)        
     September 30,
2012 		    December 31,
2011 		 
ASSETS     

Current assets:

    

Cash and cash equivalents

   $ 24,781      $ 135,843   

Short-term investments

     880,259        27,446   

Prepaid expenses and other current assets

     48,318        4,965   
  

 

 

   

 

 

 

Total current assets

     953,358        168,254   

Property and equipment, net

     1,384        2,475   

Deferred charges

     65,436        —     
  

 

 

   

 

 

 

Total assets

   $ 1,020,178      $ 170,729   
  

 

 

   

 

 

 
LIABILITIES AND STOCKHOLDERS’ DEFICIT     

Current liabilities:

    

Accounts payable and accrued expenses

   $ 2,292,055      $ 2,210,229   

Convertible notes payable

     5,827,588        21,827,588   

Notes payable

     6,410,000        5,900,000   

Accrued interest on notes payable

     806,433        486,691   

Deferred revenue

     73,730        —     

Other current liabilities

     74,976        —     
  

 

 

   

 

 

 

Total current liabilities

     15,484,782        30,424,508   

Contingent royalty

     16,000,000        —     

Deferred revenue, net of current portion

     1,234,982        —     

Other long-term liabilities

     33,750        —     
  

 

 

   

 

 

 

Total liabilities

     32,753,514        30,424,508   
  

 

 

   

 

 

 

Commitments and contingencies

    

Series F convertible redeemable preferred stock, $.01 par value; 200,000 shares designated; 12,000 shares issued and outstanding at September 30, 2012 and December 31, 2011, (liquidation preference of $300,000 at September 30, 2012)

     364,208        348,444   
  

 

 

   

 

 

 

Stockholders’ deficit:

    

Preferred stock, $.01 par value; 1,000,000 shares authorized; 25,000 shares designated Convertible Series A, 500,000 shares designated Convertible Series D and 800 shares designated Convertible Series E; no shares issued and outstanding at September 30, 2012 and December 31, 2011, respectively

     —          —     

Common stock, $.01 par value; 80,000,000 shares authorized at September 30, 2012 and December 31, 2011; 30,635,720 issued and outstanding at September 30, 2012 and December 31, 2011

     306,357        306,357   

Additional paid-in capital

     166,155,091        166,170,855   

Accumulated other comprehensive loss

     (324,554 )      (31,367 ) 

Deficit accumulated during development stage

     (198,234,438 )      (197,048,068 ) 
  

 

 

   

 

 

 

Total stockholders’ deficit

     (32,097,544 )      (30,602,223 ) 
  

 

 

   

 

 

 

Total liabilities and stockholders’ deficit

   $ 1,020,178      $ 170,729   
  

 

 

   

 

 

 

The accompanying notes are an integral part of the condensed consolidated financial statements.

 

3

Table of Contents

Alseres Pharmaceuticals, Inc.

(A Development Stage Company)

Condensed Consolidated Statements of Comprehensive Loss

(Unaudited)

 

     Three Months Ended
September 30, 		    Nine Months Ended
September 30, 		    Period from
October 16, 1992
(inception) to
September 30,
2012 		 
     2012     2011     2012     2011    

Revenues

   $ 12,288      $ —        $ 512,288      $ —        $ 1,412,288   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Operating expenses:

          

General and administrative

     437,513        512,453        1,302,552        1,681,332        70,117,440   

Research and development

     9,466        24,426        50,705        108,380        116,092,303   

Sublicense and option fees

     25,614        —          25,614        —          25,614   

Purchased in-process research and development

     —          —          —          —          12,146,544   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Operating expenses before accrual reversal

     472,593        536,879        1,378,871        1,789,712        198,381,901   

Accrual reversal

     —          —          —          (561,195 )     (561,195 )
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total operating expenses

     472,593        536,879        1,378,871        1,228,517        197,820,706   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Loss from operations

     (460,305 )      (536,879 )      (866,583 )     (1,228,517 )     (196,408,418 ) 

Interest expense

     (111,916 )      (475,607 )      (321,029 )     (1,394,616 )     (14,810,139 )

Investment income

     60        129        337        629        7,705,341   

Other income (expense), net

     —          58,814       905        58,814        (1,473,159 )

Gain on early extinguishment of debt

     —          —          —          —          6,277,100   

Forgiveness of debt

     —          476,837        —          476,837       476,837   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net loss

     (572,161 )      (476,706 )      (1,186,370 )     (2,086,853 )     (198,232,438 )

Preferred stock beneficial conversion feature

     —          —          —          —          (8,062,712 )

Accrual of preferred stock dividends and modification of warrants held by preferred stock stockholders

     —          —          —          —          (1,229,589 )
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net loss attributable to common stockholders

     (572,161 )      (476,706 )      (1,186,370 )     (2,086,853 )     (207,524,739 )

Other comprehensive income

          

Net change in unrealized loss on marketable securities

     (286,130 )      —          (293,187 )     —          (293,187 )
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Comprehensive loss

   $ (858,291 )    $ (476,706 )    $ (1,479,557 )   $ (2,086,853 )   $ (207,817,926 )
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Basic and diluted net loss attributable to common stockholders per share

   $ (0.02 )    $ (0.02 )    $ (0.04 )   $ (0.07 )  

Weighted average common shares outstanding

     30,635,720        31,662,313        30,635,720        28,934,559     
  

 

 

   

 

 

   

 

 

   

 

 

   

The accompanying notes are an integral part of the condensed consolidated financial statements.

 

4

Table of Contents

Alseres Pharmaceuticals, Inc.

(A Development Stage Company)

Condensed Consolidated Statements of Cash Flows

(Unaudited)

 

                 Period from
October 16, 1992
(inception) to
September 30,
2012 		 
     Nine Months Ended September 30,    
     2012     2011    

Cash flows from operating activities:

      

Net loss

   $ (1,186,370 )    $ (2,086,853 )   $ (198,232,438 ) 

Adjustments to reconcile net loss to net cash used for operating activities:

      

Purchased in-process research and development

     —          —          12,146,544   

Write-off of acquired technology

     —          —          3,500,000   

Loss on disposition of assets

     —          3,391        3,391   

Interest expense settled through issuance of notes payable

     —          —          350,500   

Expenses satisfied with the issuance of stock

     —          28,680        28,680   

Forgiveness of debt

     —          (476,837 )      (476,837 ) 

Gain on early extinguishment of debt

     —          —          (6,277,100 ) 

Non-cash gain on restricted stock valuation

     —          (58,814 )      (58,814 ) 

Non-cash interest expense

     —          —          3,966,394   

Non-cash charges related to options, warrants and common stock

     —          834        11,115,437   

Amortization of financing costs

     —          6,948        25,188   

Amortization and depreciation

     1,091        40,217        2,891,757   

Changes in operating assets and liabilities:

      

(Increase) decrease in prepaid expenses and other current assets

     (43,353 )      (32,859 )      457,010   

Increase in deferred charges

     (65,436 )      —          (65,436 ) 

Increase (decrease) in accounts payable and accrued expenses

     81,826        (781,764 )     1,996,228   

Increase in accrued interest payable

     319,742        1,386,239        8,134,539   

Increase in deferred revenue

     162,712        —          162,712   

Increase in current liabilities

     74,976        —          74,976   

Increase in other long-term liabilities

     33,750        —          33,750   

Decrease in accrued lease

     —          (96,425 )      —     
  

 

 

   

 

 

   

 

 

 

Net cash used for operating activities

     (621,062 )      (2,067,243 )      (160,223,519 ) 
  

 

 

   

 

 

   

 

 

 

Cash flows from investing activities:

      

Cash acquired through Merger

     —          —          1,758,037   

Purchases of property and equipment

     —          (2,373 )      (1,654,487 ) 

Proceeds from the sale of property and equipment

     —          3,430        3,430   

Decrease in security deposits and other assets

     —          113,657        —     

Decrease in indemnity fund

     —          144        —     

Purchases of marketable securities

     —          —          (132,004,923 ) 

Sales and maturities of marketable securities

     —          —          132,004,923   
  

 

 

   

 

 

   

 

 

 

Net cash provided by investing activities

     —           114,858        106,980   
  

 

 

   

 

 

   

 

 

 

 

5

Table of Contents

Alseres Pharmaceuticals, Inc.

(A Development Stage Company)

Condensed Consolidated Statements of Cash Flows (continued)

(Unaudited)

 

Condensed Consolidated Statements of Cash Flows (continued)
                   Period from
October 16, 1992
(inception) to
September 30,
2012 		 
     Nine Months Ended September 30,     
     2012      2011     

Cash flows from financing activities:

        

Proceeds from issuance of common stock

     —           —           66,731,339   

Buyback of common stock

     —           —           (26,356 ) 

Proceeds from issuance of preferred stock

     —           —           39,922,170   

Preferred stock conversion inducement

     —           —           (600,564 ) 

Proceeds from issuance of promissory notes

     510,000         1,940,000         58,995,000   

Proceeds from issuance of convertible debentures

     —           —           9,000,000   

Principal payments of notes payable/repurchase of debt

     —           —           (7,750,667 ) 

Dividend payments on Series E Cumulative Convertible Preferred Stock

     —           —           (516,747 ) 

Payments of financing costs

     —           —           (5,612,855 ) 
  

 

 

    

 

 

    

 

 

 

Net cash provided by financing activities

     510,000         1,940,000         160,141,320   
  

 

 

    

 

 

    

 

 

 

Net (decrease) increase in cash and cash equivalents

     (111,062 )       (12,385 )       24,781   

Cash and cash equivalents, beginning of period

     135,843         98,514         —     
  

 

 

    

 

 

    

 

 

 

Cash and cash equivalents, end of period

   $ 24,781       $ 86,129       $ 24,781   
  

 

 

    

 

 

    

 

 

 

Supplemental cash flow disclosures:

        

Cash paid for interest

   $ —         $ —         $ 628,406   

Supplemental disclosure of non-cash financing activity:

        

Conversion of notes payable to common stock

   $ —         $ —         $ 7,172,412   

Capital contribution related to forgiveness of accrued interest

   $ —         $ —         $ 6,328,306   

Accrued interest reclassified in connection with conversion of Series F convertible redeemable preferred stock to common stock

   $ —         $ —         $ 640,874   

Supplemental disclosure of other non-cash transactions:

        

Receipt of marketable securities as payment for license agreement

   $ 1,146,000       $ —         $ 1,146,000   

The accompanying notes are an integral part of the condensed consolidated financial statements.

 

6

Table of Contents

Alseres Pharmaceuticals, Inc.

(A Development Stage Company)

Notes to Condensed Consolidated Financial Statements (Unaudited)

September 30, 2012

1. Nature of Operations and Basis of Presentation

Nature of Operations

Alseres Pharmaceuticals, Inc. and its subsidiaries (the “Company”) is a biotechnology company engaged in the development of therapeutic and diagnostic products primarily for disorders in the central nervous system. The Company was founded in 1992 and merged with a publicly held company in 1995 (the “Merger”) whereby the Company changed its name to Boston Life Sciences, Inc. Effective June 7, 2007, the Company changed its name to Alseres Pharmaceuticals, Inc. During the period from inception through September 30, 2012, the Company has devoted substantially all of its efforts to business planning, raising financing, furthering the research and development of its technologies, and corporate partnering efforts. Accordingly, the Company is considered to be a “development stage enterprise” as defined in Accounting Standards Codification 915 (ASC 915) Development Stage Entities and will continue to be so until the commencement of commercial operations. Our development stage started on October 16, 1992 and has continued through September 30, 2012, and is expected to continue for the foreseeable future.

As of September 30, 2012, we had experienced total net losses since inception of approximately $207,525,000, stockholders’ deficit of approximately $32,098,000 and a net working capital deficit of approximately $14,531,000. For the foreseeable future, we expect to experience continuing operating losses and negative cash flows from operations as we execute our current business plan. The cash and cash equivalents available at September 30, 2012 will not provide sufficient working capital to meet our anticipated expenditures for the next twelve months. We believe that the minimal cash and cash equivalents available as of November 1, 2012, our ability to liquidate our short-term investments and minimal operating capital committed by our lead investor should enable us to meet our anticipated cash expenditures through November 2012.

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Accordingly, these financial statements do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements.

The interim unaudited condensed consolidated financial statements contained herein include, in management’s opinion, all adjustments necessary for a fair statement of the financial position, results of operations, and cash flows for the periods presented. The results of operations for the interim period shown on this report are not necessarily indicative of results for a full year. These financial statements should be read in conjunction with the Company’s consolidated financial statements and notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2011.

The accompanying condensed consolidated financial statements have been prepared on a basis which assumes that the Company will continue as a going concern which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The uncertainty inherent in the need to raise additional capital and the Company’s recurring losses from operations raise substantial doubt about the Company’s ability to continue as a going concern. The condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Reclassification

Certain reclassifications have been made to the prior year’s condensed consolidated statements of comprehensive loss to conform to the current year presentation.

2. Summary of Significant Accounting Policies

Cash and Cash Equivalents

Cash equivalents are short-term, highly liquid financial instruments that are readily convertible to cash and have maturities of 90 days or less from the date of purchase. As of September 30, 2012 and December 31, 2011, cash equivalents consisted of money market funds.

 

7

Table of Contents

Short-term Investments

The Company has designated its marketable securities as of each balance sheet date as available-for-sale securities and accounts for them at their respective fair values. Marketable securities are classified as short-term or long-term investments based on the nature of these securities and the availability of these securities to meet current operating requirements. Marketable securities that are readily available for use in current operations are classified as short-term available-for-sale securities and are reported as a component of current assets in the accompanying condensed consolidated balance sheets. The Company reviews all available-for-sale securities at each period end to determine if they remain available-for-sale based on the Company's then current intent and ability to sell the security if it is required to do so. As of September 30, 2012, the Company’s short-term investments include shares of common stock in Navidea Biopharmaceutical, Inc. (“NAVB”) and FluoroPharma Medical, Inc. (“FPMI”). The unrealized loss associated with these marketable securities has been determined to be temporary and therefore has been included in other comprehensive loss as a component of stockholders’ deficit.

Fair Value Measurements

The carrying amounts of the Company’s cash and cash equivalents, prepaid expenses, trade payables and accrued expenses approximate their fair value due to the short-term nature of these instruments. Short-term investments consist of available-for-sale-securities as of September 30, 2012 and December 31, 2011 and are carried at fair value. A contingent royalty liability resulted from the election by certain purchasers of the Company’s Convertible Promissory Note Purchase Agreement (the “Note Purchase Agreement”) to convert a total of $16,000,000 in debt obligation into a right to receive future royalties on net sales of the Company’s Molecular Imaging Products, in accordance with the terms of the Note Purchase Agreement as amended. The Company is in the process of obtaining a third party valuation for this contingent royalty liability which will be completed prior to the issuance of the Company’s audited financial statements. Due to significant unobservable inputs used to arrive at the fair value of the contingent royalty liability, the third party valuation could be significantly different from our current carrying value of $16,000,000 as of September 30, 2012. It is not practicable to estimate the fair value of the Company’s convertible debt. However, it is likely that the fair value of the debt would be materially less than the carrying value of the debt because the conversion price of $2.50 is higher than the Company’s stock price of $0.14 as of September 30, 2012 and the Company currently does not have the resources to repay the convertible debt. (See Note11)

Revenue Recognition

Our revenues have been generated primarily through sublicense and option agreements related to our Altropane product. The terms of these agreements generally contain multiple elements, or deliverables, which have included (i) licenses or options to obtain licenses to our technology; (ii) technology transfer obligations related to the licenses and (iii) research, development, regulatory and commercialization activities to be performed on our behalf. Payments to the Company under these arrangements typically include one or more of the following: non-refundable, up-front license fees; option exercise fees; milestone payments; and royalties on future product sales.

The Company evaluates multiple element revenue arrangements under FASB ASC 605-25, Multiple-Element Arrangements (as amended by ASU No. 2009-13). In addition to the form of the arrangement, the substance of the arrangement is also considered in determining whether separate agreements entered into, at or near the same time, that include elements that are interrelated or interdependent should be treated as one multiple-element arrangement. If the Company concludes that separate agreements represent one arrangement, then all the elements in the separate agreements are combined into one multiple-element arrangement for accounting purposes.

The Company concluded that the Sublicense Agreement entered into with Navidea Biopharmaceuticals and the Amended and Restated License Agreement entered into with Harvard effective July 31, 2012, should be accounted for as a single unit of accounting in accordance with the rules set forth in FASB ASC 605-25.

We considered a variety of factors in determining the appropriate method of accounting for our licensing agreements, including whether the various elements could be separated and accounted for individually as separate units of accounting. Where there are multiple deliverables identified within the licensing agreement that are combined into a single unit of accounting, revenues are deferred and recognized over the expected period of performance. The specific methodology for the recognition of the revenue is determined on a case-by-case basis according to the facts and circumstances of the applicable agreement.

Revenues from non-refundable license fees are recognized upon receipt of the payment if the license has stand-alone value, we do not have ongoing involvement or obligations, and we have determined the best estimate of the selling price for any undelivered items. When non-refundable license fees do not meet all of these criteria, the license revenues are recognized over the expected period of performance.

The Company’s deliverables under the Sublicense Agreement with Navidea include granting a license of rights and transferring technology (“know-how”) related to Altropane also called [123 I]-E-IACFT Injection and an affirmative obligation to ensure that the Harvard agreement remains in full force and effect. Under the terms of the Amended and Restated License Agreement with Harvard, the Company’s deliverables included (i) the use of reasonable efforts to effect introduction of the licensed products into the commercial market as soon as practicable, consistent with sound and reasonable business practices and judgment and (ii) until expiration of the agreement, the Company shall endeavor to

 

8

Table of Contents

keep licensed product reasonably available to the public. The Company determined that pursuant to the accounting guidance governing revenue recognition on multiple element arrangements, the granting of a license of rights, the transfer of technology (“know-how”) related to Altropane and our continuing obligations to Harvard set forth in the Amended and Restated License Agreement were not separable and, accordingly, are being treated as a single unit of accounting. The upfront sublicense execution payment of $175,000 in cash and the market value of $1,146,000 for the 300,000 shares of Navidea common stock as of July 31, 2012 were recorded as deferred revenue. Revenue will be recognized ratably from the date the sublicense agreement became effective (July 31, 2012) through the expected life of the last to expire issued and sublicensed U.S. patent for Altropane (June 2030).

We will periodically review our expected period of substantial involvement under the agreements that provide for non-refundable up-front payments and license fees. We will adjust the amortization periods when appropriate to reflect changes in assumptions relating to the duration of our expected involvement. We could accelerate revenue recognition for non-refundable upfront payments or license fees in the event of an early termination of the agreements. Alternatively, we could decelerate such revenue recognition if our period of involvement is extended. While changes to such estimates have no impact on our reported cash flows, our reported revenue is significantly influenced by our estimates of the period over which our obligations are expected to be performed and, therefore, over which revenue will be recognized.

The sublicense agreement also provides for contingent milestone payments to the Company of up to $2.9 million and the issuance of up to an additional 1.15 million shares of Navidea common stock. Milestone payments of $2.5 million and the issuance of 550,000 shares of Navidea common stock will occur at the time of product registration. The Company will be issued an additional 400,000 shares of Navidea common stock when certain cumulative net sales of the approved product are achieved. In addition, the license terms anticipate royalties on yearly net sales of the approved product which are consistent with industry-standard terms and certain license extension fees, payable in cash and shares of common stock, in the event certain milestones are not met.

Revenues associated with substantive, at-risk milestones pursuant to our licensing agreements are recognized upon achievement of the milestones. We consider a milestone to be substantive at the inception of the arrangement if it is commensurate with either our performance to achieve the milestone or the enhancement of the value of the delivered item as a result of a specific outcome resulting from our performance to achieve the milestone, it relates solely to past performance and it is reasonable relative to all of the deliverables and payment terms within the arrangement. Non-refundable contingent future amounts receivable in connection with future events specified in our licensing agreements that are not considered milestones will be recognized as revenue when payments are earned by our counterparties through completion of any underlying performance obligations, the amounts are fixed or determinable and collectability is reasonably assured.

Comprehensive Income (Loss)

On January 1, 2012, the Company adopted the new presentation requirements under ASU 2011-05, “ Presentation of Comprehensive Income ”. ASU 2011-05 requires companies to present the components of net income and the components of other comprehensive income either as one continuous statement or as two consecutive statements. As ASU 2011-05 impacts presentation only, it had no effect on the Company’s condensed consolidated financial statements for the three and nine months ended September 30, 2012.

3. Accounts Payable and Accrued Expenses

The Company’s accounts payable and accrued expenses consisted of the following:

 

     September 30, 2012      December 31, 2011  

Research and development expenses

   $ 1,343,230       $ 1,316,095   

Professional fees

     766,249         715,672   

General and administrative expenses

     107,004         99,746   

Compensation related expenses

     75,572         78,716   
  

 

 

    

 

 

 
   $ 2,292,055       $ 2,210,229   
  

 

 

    

 

 

 

4. Deferred Revenue

The Company applied the guidance in SEC Staff Accounting Bulletin (SAB) 104, Revenue Recognition, to determine the appropriate revenue recognition period for the upfront sublicense execution payment received from Navidea Biopharmaceuticals. Advance payments received in excess of amounts earned are classified as deferred revenue until earned. The upfront sublicense execution payment of $175,000 in cash and the market value of $1,146,000 for the 300,000 shares of Navidea common stock as of July 31, 2012 were recorded as deferred revenue. Revenue will be recognized ratably from the date the sublicense agreement became effective (July 31, 2012) through the expected life of the last to expire issued and sublicensed U.S. patent for Altropane (June 2030).

 

9

Table of Contents

As of September 30, 2012, the Company had total unearned revenue of $1,308,712. Unearned revenue of $73,730 is reflected as a current liability and $1,234,982 is classified as a long-term liability in the condensed consolidated balance sheet.

5. Net Loss per Share

Basic and diluted net loss per share attributable to common stockholders has been calculated by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. All potentially dilutive common shares have been excluded from the calculation of weighted average common shares outstanding since their inclusion would be anti-dilutive.

Stock options to purchase approximately 3.0 million shares of common stock were outstanding at September 30, 2012, but were not included in the computation of diluted net loss per common share because they were anti-dilutive. Stock options and warrants to purchase approximately 3.6 million shares of common stock were outstanding at September 30, 2011, but were not included in the computation of diluted net loss per common share because they were anti-dilutive. In computing diluted earnings per share, common stock equivalents in the form of convertible redeemable preferred stock were not included in the calculation of net loss per share as their inclusion would be anti-dilutive. The exercise of stock options outstanding at September 30, 2012 could potentially dilute earnings per share in the future.

6. Accounting for Stock-Based Compensation

We have one stock option plan under which we can issue both nonqualified and incentive stock options to employees, officers, consultants and scientific advisors of the Company. At September 30, 2012, the 2005 Stock Incentive Plan (the “2005 Plan”) provided for the issuance of options, restricted stock, restricted stock units, stock appreciation rights or other stock-based awards to purchase 3,450,000 shares of our common stock. The 2005 Plan contains a provision that allows for an annual increase in the number of shares available for issuance under the 2005 Plan on the first day of each of the Company’s fiscal years during the period beginning in fiscal year 2006 and ending on the second day of fiscal year 2014. The annual increase in the number of shares shall be equal to the lowest of 400,000 shares; 4% of the Company’s outstanding shares on the first day of the fiscal year; and an amount determined by the Board of Directors. No increase in the number of shares available for issuance was made in January 2012.

We also have outstanding stock options in three other stock option plans, the 1998 Omnibus Plan, the Amended and Restated Omnibus Stock Option Plan and the Amended and Restated 1990 Non-Employee Directors’ Non-Qualified Stock Option Plan. These plans have expired and no future issuance of awards is permissible.

Our Board of Directors determines the term, vesting provisions, price, and number of shares for each award that is granted. The term of each option cannot exceed ten years.

No stock-based compensation expense was recorded during the three and nine months ended September 30, 2012. No stock-based compensation expense was recorded during the three months ended September 30, 2011. Stock-based compensation expense of $834 was recorded during the nine months ended September 30, 2011.

We use the Black-Scholes option-pricing model to calculate the fair value of each option grant on the date of grant. No stock options were granted during the three months ended September 30, 2012 and 2011.

A summary of our outstanding stock options for the nine months ended September 30, 2012 and 2011 is presented below.

 

     2012      2011  
     Shares     Weighted
Average
Exercise Price 		     Shares     Weighted
Average
Exercise Price 		 

Outstanding at beginning of year

     3,636,480      $ 1.55         3,650,443      $ 1.59   

Granted

     —          —           —          —     

Exercised

     —          —           —          —     

Forfeited and expired

     (625,500 )      1.75         (7,963 )      14.23   
  

 

 

   

 

 

    

 

 

   

 

 

 

Outstanding at end of period

     3,010,980      $ 1.51         3,642,480      $ 1.56   
  

 

 

   

 

 

    

 

 

   

 

 

 

Options exercisable at end of period

     3,010,980      $ 1.51         3,642,480      $ 1.56   
  

 

 

   

 

 

    

 

 

   

 

 

 

 

10

Table of Contents

The following table summarizes information about stock options outstanding and exercisable at September 30, 2012:

 

Range of Exercise Prices

   Number Outstanding      Weighted Average
Remaining
Contractual Life 		   Weighted Average
Exercise Price 		 

$1.15 — $1.36

     2,287,500       1.7 years    $ 1.15   

$2.00 — $3.00

     539,980       3.0 years      2.33   

$3.10 — $4.65

     155,000       5.1 years      3.17   

$4.99 — $6.96

     28,500       1.3 years      5.47   
  

 

 

    

 

  

 

 

 
     3,010,980       2.1 years    $ 1.51   

There was no intrinsic value of outstanding options and exercisable options as of September 30, 2012. As of September 30, 2012, 809,172 shares were available for grant under the 2005 Stock Incentive Plan.

7. Notes Payable and Debt

 

Convertible Notes Payable to Significant Stockholders

          September 30, 2012      December 31, 2011  

Unsecured convertible promissory note; interest rate of 5%; due December 31, 2010

      $ 1,344,828       $ 4,655,173   

Unsecured convertible promissory note; interest rate of 5%; due December 31, 2010

     BCF         4,482,760         10,000,000   

Unsecured convertible promissory note; interest rate of 5%; due December 31, 2010

     BCF         —           2,172,415   

Unsecured convertible promissory note; interest rate of 5%; due December 31, 2010

        —           5,000,000   
     

 

 

    

 

 

 

Aggregate carrying value

      $ 5,827,588       $ 21,827,588   
     

 

 

    

 

 

 

Effective July 31, 2012, Robert Gipson, Thomas Gipson, Arthur Koenig and Ingalls & Snyder Value Partners LLP, all lenders to the Company under a Convertible Note Purchase Agreement originally executed in 2007, elected to convert $16,000,000 of principal outstanding under the promissory notes to a royalty on future net sales of the Company’s Altropane product. All other rights under the Convertible Note Purchase Agreement related to the $16,000,000 of principal were waived by the lenders. As of September 30, 2012, the contingent royalty liability resulting from the conversion is classified in the condensed consolidated balance sheet as a long-term liability.

Also effective July 31, 2012, Arthur Koenig and Ingalls & Snyder Value Partners LLP executed the Sixth Amendment to Convertible Note Purchase Agreement. The amendment provides that the two lenders waive any and all rights to convert the $5,827,588 of principal still outstanding under the promissory notes into royalty on future sales of the Company’s Altropane product, while retaining their right to convert all or any portion of the remaining convertible debt to common stock of the Company at $2.50 per share.

The Company has demonstrated financial difficulties. Further, the intent of the above convertible debt conversion and modifications was to allow for continued product development and was considered to be the most viable option for the Company. Based on these factors, these transactions were considered to be concessions and were accounted for as a troubled debt restructuring under the guidance of ASC 470-60-55. As prescribed in ASC 470-60-35-11, when estimates are used relating to the maximum future cash payments as is this case, no gain shall be recognized until the estimated maximum future cash payments fall below the carrying value of the debt before restructuring. Based on the best evidence available, the Company concluded that the estimated maximum future cash payments are not less than the carrying amount of $16,000,000; therefore, no adjustment to the carrying amount was necessary as of September 30, 2012.

No interest expense was incurred related to the convertible notes payable for the three and nine months ended September 30, 2012. Interest expense totaling $362,499 and $1,087,497 was incurred related to the convertible notes payable for the three and nine months ended September 30, 2011. In December 2011, Robert Gipson and Thomas Gipson elected to convert a total of $7,172,412 of their convertible notes payable into common stock of the Company. This transaction was part of a debt reduction agreement entered into through the Fifth Amendment to Convertible Note Purchase Agreement (“Amendment”) which also provided that all interest accrued or to be accrued related to these promissory notes would be waived.

As of September 30, 2012, the holders of the convertible notes have not made any formal demand for payment of the debt which became due on December 31, 2010.

 

11

Table of Contents

Beneficial Conversion Feature (BCF)

Two of the remaining unsecured promissory notes were issued with a conversion price of $2.50 which was below the market price of the Company’s common stock on the dates the agreements were entered into and resulted in the recording of a beneficial conversion feature (“BCF”). The Company recorded a BCF of $1,400,000 on (the “ISVP”) note and a BCF of $380,000 on (the “2008 RG”) note which were recognized as a decrease in the carrying value and an increase to additional paid-in capital. All related BCF expense has been fully recognized as interest expense using the effective interest method as of December 31, 2010.

Promissory Notes

 

Demand Notes Payable to Significant Stockholder

   September 30, 2012      December 31, 2011  

Unsecured demand note payable; interest rate of 7%: issued December 2009

   $ 350,000       $ 350,000   

Unsecured demand notes payable; interest rate of 7%: issued January 2010 — December 2010

     3,310,000         3,310,000   

Unsecured demand notes payable; interest rate of 7%: issued January 2011 — December 2011

     2,240,000         2,240,000   

Unsecured demand notes payable; interest rate of 7%: issued January 2012 — August 2012

     435,000         —     

Secured demand note payable; interest rate of 7%: issued September 2012

     75,000         —     
  

 

 

    

 

 

 
     6,410,000         5,900,000   

Accrued interest

     806,433         486,691   
  

 

 

    

 

 

 

Aggregate carrying value

   $ 7,216,433       $ 6,386,691   
  

 

 

    

 

 

 

Interest expense totaling $111,487 and $112,518 was incurred related to the demand notes payable for the three months ended September 30, 2012 and 2011, respectively. Interest expense totaling $319,742 and $298,742 was incurred related to the demand notes payable for the nine months ended September 30, 2012 and 2011, respectively.

According to a Schedule D/A filed with the SEC on December 27, 2011 Robert Gipson beneficially owned approximately 50.1% of the outstanding common stock of the Company as of that date. Robert Gipson, who serves as a Senior Director of Ingalls & Snyder and a General Partner of ISVP, served as a director of the Company from June 15, 2004 until October 28, 2004. According to a Schedule D/A filed with the SEC on December 27, 2011, Thomas Gipson beneficially owned approximately 15.2% of the outstanding common stock of the Company as of that date. According to a Schedule 13G/A filed with the SEC on June 7, 2011, Arthur Koenig beneficially owned approximately 7% of the outstanding common stock of the Company on June 1, 2011. According to a Schedule 13G/A filed with the SEC on February 2, 2012, ISVP owned approximately 9.99% of the outstanding common stock of the Company as of December 31, 2011. According to a Schedule 13G/A filed with the SEC on February 7, 2012, Ingalls & Snyder LLC beneficially owned approximately 9.99% of the outstanding common stock of the Company on December 31, 2011.

Contingent Royalty Liability

Effective July 31, 2012, Robert Gipson, Thomas Gipson, Arthur Koenig and Ingalls & Snyder Value Partners LLP, all lenders to the Company under a Convertible Note Purchase Agreement originally executed in 2007, elected to convert $16,000,000 of principal outstanding under the promissory notes to a royalty on future net sales of the Company’s Altropane product.

The Company is in the process of obtaining a third party valuation for this contingent royalty liability which will be completed prior to the issuance of the Company’s audited financial statements. Due to significant unobservable inputs used to arrive at the fair value of the contingent royalty liability, the third party valuation could be significantly different from our current carrying value of $16,000,000. As of September 30, 2012, the contingent royalty liability is recorded in the condensed consolidated balance sheet as a long-term liability.

 

12

Table of Contents

8. Convertible Preferred Stock

The Company’s Series F Convertible, Redeemable Preferred Stock (“Series F Stock”) can be converted into 25 shares of common stock pursuant to the conversion terms of the Series F Stock contained in the Certificate of Designation for the Series F Stock. All shares of Series F Stock were sold to Robert Gipson in 2009 at $25 per share, yielding the Company aggregate proceeds of $4,600,000. As of September 30, 2012, 12,000 shares of Series F Stock were outstanding and held by Robert Gipson.

9. Commitments and Contingencies

We recognize and disclose commitments when we enter into executed contractual obligations with third parties. We accrue contingent liabilities when it is probable that future expenditures will be made and such expenditures can be reasonably estimated.

On March 13, 2012 the Company received notice that Children’s Hospital Boston and Children’s Medical Center Corporation had filed a lawsuit in Middlesex Superior Court, Middlesex County, Massachusetts seeking to recover amounts alleged to be owed by the Company to the plaintiffs totaling $642,906. The Company estimates that the total amounts claimed in the lawsuit are slightly higher than the actual amounts owed and will pursue all legal remedies available to it to defend this claim.

On May 2, 2012 the Company received notice that Biostorage Technologies, Inc. had filed a lawsuit in Marion Superior/Circuit Court, Marion County, Indiana seeking to recover amounts alleged to be owed by the Company to the plaintiffs totaling $119,363. The Company believes that the total amounts claimed in the Biostorage lawsuit are significantly overstated. The Company intends to pursue all available legal and equitable remedies to defend this claim.

Sublicense Agreement with Navidea Biopharmaceuticals, Inc.

Effective July 31, 2012, the Company entered into an exclusive, worldwide sublicense agreement with Navidea Biopharmaceuticals, Inc., (“Navidea”) for the research, development and commercialization of [123 I]-E-IACFT Injection (CFT), also called Altropane ® . CFT is an Iodine-123 radiolabeled imaging agent which is being developed as an aid in the diagnosis of Parkinson’s disease and movement disorders.

Under the terms of the sublicense agreement, Navidea will use its best commercial efforts to develop and launch Altropane in accordance with an agreed to development plan for the product. Navidea will be responsible for conducting and funding all future development, regulatory filings, manufacturing and global commercialization of Altropane. The Company will have no further cost obligations related to Altropane. In connection with the execution of the agreement Navidea made a one-time sublicense execution payment to the Company of $175,000. In addition, the Company was issued 300,000 shares of Navidea common stock (“NAVB”) which had a market value of $1,146,000 based on the NYSE closing price of $3.82 per share on July 31, 2012. Our shares of Navidea common stock are currently subject to Rule 144 restrictions. On September 28, 2012, Navidea filed a Registration Statement on Form S-3 with the Securities and Exchange Commission (“SEC”) that will remove the restriction and permit the Company to sell the shares.

The sublicense agreement also provides for contingent milestone payments to the Company of up to $2.9 million and the issuance of up to an additional 1.15 million shares of Navidea common stock. Milestone payments of $2.5 million and the issuance of 550,000 shares of Navidea common stock will occur at the time of product registration. The Company will be issued an additional 400,000 shares of Navidea common stock when certain cumulative net sales of the approved product are achieved. In addition, the license terms anticipate royalties on yearly net sales of the approved product which are consistent with industry-standard terms and certain license extension fees, payable in cash and shares of common stock, in the event certain milestones are not met.

Either party may terminate the agreement if the other party materially breaches the agreement and such breach remains uncured for 60 days after the date of notice of such breach. Navidea has the right to terminate the agreement at any time for any or no reason, in part or in its entirety, upon providing sixty day notice to the Company. If neither party terminates the agreement, then the agreement will remain in effect until the occurrence of the last royalty expiration date as such term is defined in the sublicense agreement.

Amended and Restated License Agreement with the President and Fellows of Harvard College

Simultaneous with the signing of the Navidea Sublicense Agreement, the Company entered into an Amended and Restated License Agreement with the President and Fellows of Harvard College (“Harvard”) which resulted in the revision of certain financial terms regarding the royalty payable to Harvard, the percentage of non-royalty income payable to Harvard by the Company and the timing of said payments. Pursuant to the agreement, the Company is obligated to make a cash payment of $8,750 to Harvard in connection with the receipt of the cash consideration of $175,000 received from Navidea upon execution of the sublicense agreement. This payment is due to Harvard within 30 days following the first commercial sale of the Altropane product. The Company is also obligated to transfer to Harvard 15,000 shares of the Navidea Biopharmaceutical, Inc. stock received as part of the sublicense agreement on the earlier of 5 days following the filing of the form S-3 by Navidea or December 31, 2012.

In addition it was agreed that the Company will pay Harvard $25,000 of the $500,000 consideration Navidea Biopharmaceuticals paid to the Company in connection with the January 25, 2012 Option Agreement. Harvard has agreed to defer receipt of such payment until 30 days following the first commercial sale of the Altropane product.

 

13

Table of Contents

10. Income taxes

The Company is subject to both federal and state income tax for the jurisdiction within which it operates. Within these jurisdictions, the Company is open to examination for tax years ended December 31, 2009 through December 31, 2011. The U.S. Internal Revenue Service (IRS) has completed an audit of tax years 2007 and 2008 and has informed us that no adjustments to the federal tax returns as filed will be proposed as a result of the audit. However, because we are carrying forward income tax attributes such as a net operating loss (“NOL”) from 2006, these attributes can still be audited when utilized on returns filed in the future.

11. Fair Value Measurements

The fair value hierarchy prioritizes observable and unobservable inputs used to measure fair value into three broad levels:

Level 1 — unadjusted quoted prices in active markets for identical securities;

Level 2 — unadjusted quoted prices in markets that are not active,

Level 3 — significant unobservable inputs, including our own assumptions in determining fair value

The following table summarizes the financial assets that we measured at fair value as of September 30, 2012 and December 31, 2011.

 

     September 30, 2012
Fair Value 		     Input Level      December 31, 2011
Fair Value 		     Input Level  

Short-term investments

   $ 880,259         Level 1       $ 27,446         Level 2   
  

 

 

       

 

 

    

As of September 30, 2012, the Company’s Level 1 short-term investments consist of 300,000 shares of Navidea Biopharmaceuticals, Inc. common stock. These shares are traded on the NYSE under the symbol NAVB. Our shares of Navidea common stock are currently subject to Rule 144 restrictions. On September 28, 2012, Navidea filed a Registration Statement on Form S-3 with the Securities and Exchange Commission (“SEC”) that will remove the restriction and permit the Company to sell the shares.

As of September 30, 2012, the Company determined that the FluoroPharma Medical, Inc. common stock previously classified as a Level 2 asset should be reclassified to Level 1 based on the increased liquidity of the shares due to more stable trading volume in the open market.

As of December 31, 2011, the Company’s Level 2 short-term investments consisted of 39,209 shares of FluoroPharma Medical, Inc. stock. These shares traded on the OTC Bulletin Board (“OTCBB”) under the symbol FPMI. Our shares were subject to Rule 144 restrictions and traded on very thin volume in the open market. Based on these two factors the Company classified these shares as a Level 2 asset.

The Company did not have any other non-financial assets or liabilities that were measured or disclosed at fair value for the period ended September 30, 2012 or December 31, 2011. It is not practicable to estimate the fair value of the Company’s convertible debt. However, it is likely that the fair value of the debt would be materially less than the carrying value of the debt because the conversion price of $2.50 is higher than the Company’s stock price of $0.14 as of September 30, 2012.

12. Subsequent Events

We evaluated all events or transactions that occurred after September 30, 2012 up through the date we issued these financial statements.

The Securities and Exchange Commission issued a Notice of Effectiveness of the S-3 registration statement filed by Navidea Biopharmaceuticals, Inc. on behalf of Alseres Pharmaceuticals, Inc. with an effective date of October 17, 2012. The Form S-3 covered the 300,000 shares of Navidea common stock issued to the Company on July 31, 2012. The removal of the restriction will now permit the Company to sell these shares.

Item 2 — Management’s Discussion and Analysis of Financial Condition and Results of Operations

Our management’s discussion and analysis of our financial condition and results of operations include the identification of certain trends and other statements that may predict or anticipate future business or financial results that are subject to important factors that could cause our actual results to differ materially from those indicated. See Item 1A, “Risk Factors” and also carefully review the risks outlined in other documents that we file from time to time with the SEC.

Overview

Description of Company

We are a biotechnology company focused on the development of diagnostic and therapeutic products primarily for disorders in the central nervous system, or CNS. Our clinical and preclinical product candidates are based on two proprietary technology platforms:

 

  •  

Molecular imaging program focused on the diagnosis of i) Parkinsonian Syndromes, or PS, including Parkinson’s Disease, or PD, and ii) Dementia with Lewy Bodies, or DLB;

 

  •  

Regenerative therapeutics program primarily focused on nerve repair in patients who have had significant loss of CNS function resulting from CNS trauma.

 

14

Table of Contents

Product Development — Molecular Imaging Program

Altropane Molecular Imaging Agent

The Altropane molecular imaging agent is intended to be used for the differential diagnosis of PS, including PD, and non-PS in patients with an upper extremity tremor. The Altropane molecular imaging agent is a radio labeled imaging agent that contains the radioactive element iodine isotope 123 I and binds with extremely high affinity and specificity to the dopamine transporter, or DAT. The DAT is a protein that is on the surface membrane of specialized neurons in the brain that produce dopamine, a key neurotransmitter. We believe that the amount of Altropane taken up by the brain is directly proportional to the number of DATs that are present in any given area of the brain. Since DATs are on the membrane of dopamine-producing neurons, death of these neurons results in decreased numbers of DATs. Therefore, PD, which is caused by a decreased number of dopamine producing cells, is associated with a marked decrease in the number of DATs. As a result, when Altropane is administered to patients with PD, its binding is substantially diminished as compared to patients without PD. This decrease in Altropane binding in patients with PD is the theoretical basis for using Altropane imaging as a diagnostic test for PS, including PD.

Altropane is administered by intravenous injection. Since Altropane contains radioactive 123 I, it can be used as a nuclear imaging agent that can be detected using a specialized nuclear medicine instrument known as a Single Photon Emission Computed Tomography, or SPECT, camera. The strength of the SPECT signal generated by Altropane is proportional to the number of DATs present and produces images that distinguish PS and non-PS patients. SPECT cameras are widely available in both community and academic medical centers. The scanning procedure using Altropane takes less than one hour to complete. Results of these tests are usually available the same day as the scanning procedure.

After a series of discussions with the U.S. Food and Drug Administration, or FDA, and our expert advisors, the POET-2 program was designed as a two-part Phase III program pursuant to a Special Protocol Assessment or SPA Agreement we reached with the FDA in April 2009. The first part of the program enrolled 54 subjects in a multi-center clinical study to acquire a set of Altropane images which will be used to train the expert readers in the second part of the program, as is the customary process for clinical trials of molecular imaging agents. The second portion of the Phase III, POET-2 program covered by the SPA was intended to consist of two clinical trials in up to 480 subjects in total to be conducted in parallel at up to 40 medical facilities throughout the United States. The subjects to be tested are to be 40-80 years of age and have had a tremor in their hand(s) or arm(s) for less than three years. Each subject will be assessed by a general neurologist, an Altropane imaging procedure and a Movement Disorder Specialist considered the “gold standard”. The success of the trial will be determined by measuring the diagnostic efficacy of the neurologist diagnosis compared with the diagnosis determined by the Altropane scan versus the MDS gold standard diagnosis.

On January 19, 2012 the Company entered into an Option Agreement with Navidea Biopharmaceuticals, Inc. (Amex NAVB), to license [123I]-E-IAFCT Injection (also referred to as Altropane). The option agreement provided Navidea with a 6 month period during which it had exclusive rights to license the asset and complete further diligence and the definitive license for [123I]-E-IACFT. Under the terms of the option agreement, Navidea paid Alseres an option fee of $500,000 upon signing the agreement.

On July 31, 2012 we signed an agreement with Navidea Biopharmaceuticals, Inc. to sublicense [ 123 I]-E-IACFT Injection (CFT), also called Altropane ® .The terms of the Navidea license agreement call for Navidea to assume full responsibility for the development and commercialization of Altropane on a worldwide basis. We have licensed worldwide exclusive rights to develop Altropane from Harvard University and its affiliated hospitals, which we refer to as Harvard and its Affiliates, including the Massachusetts General Hospital. The license agreement provides for milestone payments and royalties based on product sales that are consistent with industry averages for such products. The Company’s deliverables under the Sublicense Agreement with Navidea include granting a license of rights and transferring technology (“know-how”) related to Altropane and an affirmative obligation to ensure that the Harvard agreement remains in full force and effect. Under the terms of the Amended and Restated License Agreement with Harvard, the Company’s deliverables included (i) the use of reasonable efforts to effect introduction of the licensed products into the commercial market as soon as practicable, consistent with sound and reasonable business practices and judgment and (ii) until expiration of the agreement, the Company shall endeavor to keep Altropane reasonably available to the public.

Regenerative Therapeutics Program — Nerve Repair

Resource constraints have severely restricted our ability to progress our regenerative therapeutics program. On May 11, 2010, the Company was notified by Children’s Medical Center Corporation (“CMCC”) of the termination of its license agreements with the Company as a result of the Company’s lack of resources and resulting inability to comply with the performance conditions of the licenses. As of September 30, 2012 CMCC was owed approximately $77,000 in license fees and legal costs associated with the licenses and approximately $530,000 related to sponsored research contracts. Since we were unable to pay the overdue amounts within the cure periods specified in the CMCC licenses, we no longer have the rights to further develop and/or partner the axon regeneration technologies licensed from CMCC.

 

15

Table of Contents

Neurodiagnostics Opportunity

In light of the recent closing of the Navidea license, we have begun preliminary planning for the redirection of the Company.

We are presently conducting a preliminary feasibility assessment for a new business focused on organizing and operating a U.S. network of outpatient clinics focused on screening, diagnosis and monitoring of brain conditions, both neurodegenerative and trauma induced. The centers will provide screening, diagnosis and on-going monitoring of both pre-symptomatic and symptomatic patients affected by these disorders. The centers will take advantage of currently available screening tools, in-vitro diagnostics and imaging diagnostics to identify patients who are “at risk” of developing a wide array of brain disorders. We are working, on a confidential basis, with industry participants to assess possible support for the development of the potential new business including capital and human resources.

The number of Americans living with neurodegenerative movement disorders such as Parkinson’s disease (PD), and dementias like Alzheimer’s (AD) and Dementia with Lewy Bodies (DLB), is expected to grow from 20 million in 2010 to 30 million by 2030. By 2050, that number is expected to grow to 40 million. Unchecked and without accounting for loss of productivity, the annual cost of care for patients with these diseases will grow from $200 billion today to $500 billion by 2030 .

Today, PD, AD and DLB are diagnosed post-symptomatically. By the time diagnosable clinical symptoms appear, the disease is in an advanced stage. The disease has already progressed well beyond the point that current therapies have been shown to have disease modifying effects. Drugs in development are routinely tested in patients with advanced stage disease, where the drugs are least likely to have the disease modifying or arresting affect desired. What is needed are:

 

  •  

Early detection, definitive diagnostics and therapeutic drug monitoring tools; and

 

  •  

Comprehensive, longitudinal data to enable disease modifying treatments for early stage degenerative brain diseases

At present our work on this opportunity is extremely preliminary and is focused on identifying an initial location for a pilot site intended to demonstrate the proof of concept for the centers and accessing potential sources of capital. We can provide no assurance that this business will ever be launched or that the capital and human resources necessary to launch and grow the new business will be available on acceptable terms if at all.

Critical Accounting Policies and Estimates

Our discussion and analysis of our financial condition and results of operations are based upon our condensed consolidated financial statements which have been prepared by us in accordance with accounting principles generally accepted in the United States of America. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. Our estimates include those related to marketable securities, research contracts and the fair value and classification of financial instruments. We base our estimates on historical experience and on various other assumptions that we believed to be reasonable under the circumstances. Actual results may differ from these estimates under different assumptions or conditions.

Results of Operations for the Three Months Ended September 30, 2012 and 2011

For the three months ended September 30, 2012, the Company recognized revenue of $12,288. This revenue reflects the current period ratable recognition of the $1,321,000 upfront sublicense fee received from Navidea Biopharmaceuticals effective July 31, 2012. Revenue will be recognized ratably from the date the sublicense agreement became effective (July 31, 2012) through the expected life of the last to expire issued and sublicensed U.S. patent for Altropane (June 2030).

Effective July 31, 2012, the Company entered into an exclusive, worldwide sublicense agreement with Navidea Biopharmaceuticals, Inc., (“Navidea”) for the research, development and commercialization of [123 I]-E-IACFT Injection (CFT), also called Altropane ® . CFT is an Iodine-123 radiolabeled imaging agent which is being developed as an aid in the diagnosis of Parkinson’s disease and movement disorders.

Under the terms of the sublicense agreement, Navidea has agreed to use its best commercial efforts to develop and launch Altropane in accordance with an agreed to development plan for the product. Navidea will be responsible for conducting and funding all future development, regulatory filings, manufacturing and global commercialization of Altropane. The Company will have no further cost obligations related to Altropane. In connection with the execution of the agreement Navidea made a one-time sublicense execution payment to the Company of $175,000. In addition, the Company was issued 300,000 shares of Navidea common stock (“NAVB”) which had a market value of $1,146,000 based on the NYSE closing price of $3.82 per share on July 31, 2012.

Our net loss was $572,161 for the three months ended September 30, 2012 compared to a net loss of $476,706 for the three months ended September 30, 2011. The net loss for the three months ended September 30, 2012 resulted from operating expenses of approximately $473,000 and interest expense of approximately $112,000 partially offset by the recognition of the current period revenue of $12,288 related to the sublicense agreement with Navidea. The net loss of $476,706 for the three months ended September 30, 2011 was attributable to operating expenses of approximately $537,000 and interest expense of approximately $476,000 partially offset by the forgiveness of debt of $476,837 and the gain of $58,814 which resulted from a change in accounting for the value of our FluoroPharma Medical shares.

 

16

Table of Contents

Research and development expenses were $9,466 during the three months ended September 30, 2012 compared to $24,426 during the three months ended September 30, 2011. For the remainder of 2012, we will incur minimal expenses related to pre-existing commitments. Under the terms of the sublicense agreement with Navidea, the Company will no longer have any further cost obligations related to Altropane. Navidea will use its best commercial efforts to develop and launch Altropane in accordance with an agreed to development plan for the product. Navidea will be responsible for conducting and funding all future development, regulatory filings, manufacturing and global commercialization of Altropane.

Sublicense and option fees were $25,614 during the three months ended September 30, 2012. This expense reflects the $25,000 option fee due to Harvard under the terms of the Amended and Restated License Agreement. The remaining expense reflects the amortization of fees due to Harvard related to the cash and stock consideration received from the sublicense agreement with Navidea. Total cash payments of $33,750 are due to Harvard related to these transactions. The Company is amortizing total license fees of $66,050 on a straight-line basis over the estimated performance period which is the effective date of the agreements on July 31, 2012 through the patent expiration date in June 2030.

General and administrative expenses were $437,513 during the three months ended September 30, 2012 compared to $512,453 during the three months ended September 30, 2011. The decrease of $74,940 or 15% for the three months ended September 30, 2012 was attributable to (i) a reduction in patent expense of approximately $22,000 resulting from the sublicense agreement which transferred all future responsibility for such expense to Navidea; and (ii) a reduction in overhead costs of approximately $72,000 related to the expiration of our office lease in September 2011. The overhead reductions are attributable to lower rent expense and common area maintenance charges of approximately $53,000, the elimination of approximately $11,000 in non-cash charges for the amortization of leasehold improvements and the reduction of approximately $8,200 in utility expenses. In addition, office expenses attributable to equipment rental and supplies decreased by approximately $9,000. The savings realized from these reductions were partially offset by an increase of approximately $33,000 attributable to complying with additional regulatory reporting requirements and investor relations expense.

Interest expense of $111,916 was incurred during the three months ended September 30, 2012 compared to $475,607 during the three months ended September 30, 2011. The decrease of $363,691, or 77% for the three months ended September 30, 2012 was attributable to the debt reduction agreements signed in the fourth quarter of 2011. In December 2011, Robert Gipson and Thomas Gipson converted $7,172,412 of their convertible notes payable into common stock of the Company. The debt reduction agreement provided that all future interest related to these promissory notes would be waived. In November 2011, the Company further reduced its debt obligations by purchasing from Robert Gipson (the “Holder”) an unsecured promissory note, pursuant to which the Company’s wholly owned subsidiary, Neurobiologics Inc., had borrowed an aggregate principal amount of $1,000,000 (“the Note”) dated February 11, 2009. The savings associated with the debt reduction agreements were partially offset by $2,240,000 of new debt obligations entered into with Robert Gipson during 2011 and an additional $510,000 of new debt obligations entered into during 2012.

Results of Operations for the Nine Months Ended September 30, 2012 and 2011

For the nine months ended September 30, 2012, the Company recognized revenue of $512,288. This revenue represents the non-refundable option fee of $500,000 the Company received from Navidea Biopharmaceuticals on January 19, 2012 upon entering into an exclusive right to negotiate a definitive license agreement. The remaining $12,288 in revenue reflects the current period ratable recognition of the $1,321,000 upfront sublicense fee received from Navidea Biopharmaceuticals effective July 31, 2012. Revenue will be recognized ratably from the date the sublicense agreement became effective (July 31, 2012) through the expected life of the last to expire issued and sublicensed U.S. patent for Altropane (June 2030).

Effective July 31, 2012, the Company entered into an exclusive, worldwide sublicense agreement with Navidea Biopharmaceuticals, Inc., (“Navidea”) for the research, development and commercialization of [123 I]-E-IACFT Injection (CFT), also called Altropane ® . CFT is an Iodine-123 radiolabeled imaging agent which is being developed as an aid in the diagnosis of Parkinson’s disease and movement disorders.

Under the terms of the license agreement, Navidea will use its best commercial efforts to develop and launch Altropane in accordance with an agreed to development plan for the product. Navidea will be responsible for conducting and funding all future development, regulatory filings, manufacturing and global commercialization of Altropane. The Company will have no further cost obligations related to Altropane. In connection with the execution of the agreement Navidea made a one-time sublicense execution payment to the Company of $175,000. In addition, the Company was issued 300,000 shares of Navidea common stock (“NAVB”) which had a market value of $1,146,000 based on the NYSE closing price of $3.82 per share on July 31, 2012.

Our net loss was $1,186,370 for the nine months ended September 30, 2012 compared to a net loss of $2,086,853 for the nine months ended September 30, 2011. The net loss for the nine months ended September 30, 2012 resulted from operating expenses of approximately $1,379,000 and interest expense of approximately $321,000 partially offset by the recognition of $512,288 in revenue. The net loss of $2,086,853 for the nine months ended September 30, 2011 was attributable to adjusted operating expenses of approximately $1,229,000 and interest expense of approximately $1,395,000 partially offset by the forgiveness of debt of $476,837 and the gain of $58,814 which resulted from a change in accounting for the value of our FluoroPharma Medical shares.

 

17

Table of Contents

Research and development expenses were $50,705 during the nine months ended September 30, 2012 compared to $108,380 during the nine months ended September 30, 2011. For the remainder of 2012, we should incur only minimal expenses related to pre-existing commitments. Under the terms of the sublicense agreement with Navidea, the Company will no longer have any further cost obligations related to Altropane. Navidea will use its best commercial efforts to develop and launch Altropane in accordance with an agreed to development plan for the product. Navidea will be responsible for conducting and funding all future development, regulatory filings, manufacturing and global commercialization of Altropane.

Sublicense and option fees were $25,614 during the nine months ended September 30, 2012. This expense reflects the $25,000 option fee due to Harvard under the terms of the Amended and Restated License Agreement. The remaining expense reflects the amortization of fees due to Harvard related to the cash and stock consideration received from the sublicense agreement with Navidea. Total cash payments of $33,750 are due to Harvard related to these transactions. The Company is amortizing total license fees of $66,050 on a straight-line basis over the estimated performance period which is the effective date of the agreements on July 31, 2012 through the patent expiration date in June 2030.

General and administrative expenses were $1,302,552 during the nine months ended September 30, 2012 compared to $1,681,332 during the nine months ended September 30, 2011. The decrease of $378,780 or 23% for the nine months ended September 30, 2012 was attributable to (i) a reduction in employee payroll and related tax and benefit costs of approximately $109,000 resulting from reduced headcount; (ii) a reduction in consulting fees of approximately $29,000; (iii) a reduction in patent expense of approximately $18,000 resulting from the sublicense agreement which transferred all future responsibility for such expense to Navidea; and iv) a reduction in overhead costs of approximately $241,000 related to the expiration of our office lease in September 2011. The overhead reductions are attributable to lower rent expense and common area maintenance charges of approximately $175,000, the elimination of approximately $32,000 in non-cash charges for the amortization of leasehold improvements, a reduction in non-cash depreciation expense of approximately $10,000 and the reduction of approximately $22,000 in utility expenses. In addition, office expenses attributable to equipment rental and supplies decreased by approximately $11,000. The savings realized from these reductions were partially offset by an increase of approximately $39,000 attributable to complying with additional regulatory reporting requirements and investor relations expense.

Interest expense of $321,029 was incurred during the nine months ended September 30, 2012 compared to $1,394,616 during the nine months ended September 30, 2011. The decrease of $1,073,587 or 77% for the nine months ended September 30, 2012 was attributable to the debt reduction agreements signed in the fourth quarter of 2011. In December 2011, Robert Gipson and Thomas Gipson converted $7,172,412 of their convertible notes payable into common stock of the Company. The debt reduction agreement provided that all future interest related to these promissory notes would be waived. In November 2011, the Company further reduced its debt obligations by purchasing from Robert Gipson (the “Holder”) an unsecured promissory note, pursuant to which the Company’s wholly owned subsidiary, Neurobiologics Inc., had borrowed an aggregate principal amount of $1,000,000 (“the Note”) dated February 11, 2009. The savings associated with the debt reduction agreements were partially offset by $2,240,000 of new debt obligations entered into with Robert Gipson during 2011 and an additional $510,000 in new debt obligations entered into during 2012.

Liquidity and Capital Resources

As of September 30, 2012, we had experienced total net losses since inception of approximately $207,525,000, stockholders’ deficit of approximately $32,098,000 and a net working capital deficit of approximately $14,531,000. The cash and cash equivalents available at September 30, 2012 will not provide sufficient working capital to meet our anticipated expenditures for the next twelve months. We believe that the minimal cash and cash equivalents available as of November 1, 2012, our ability to liquidate our short-term investments and our ability to control certain general and administrative expenses will enable us to meet our anticipated cash expenditures through November 2012.

For the nine months ended September 30, 2012, the Company generated $675,000 in cash. The Company received of a non-refundable option fee of $500,000 in January 2012 from Navidea Biopharmaceuticals, Inc. upon signing an exclusive right to negotiate a definitive license agreement. On July 31, 2012 the Company signed an agreement with Navidea Biopharmaceuticals, Inc. to license [ 123 I]-E-IACFT Injection (CFT), also called Altropane ® , an Iodine-123 radiolabeled imaging agent, being developed as an aid in the diagnosis of Parkinson’s disease and movement disorders. In connection with the execution of this agreement, Navidea made a one-time sublicense execution payment of $175,000 to the Company.

In addition the Company was issued 300,000 shares of NAVB common stock which are currently subject to Rule 144 restrictions. On September 28, 2012, Navidea filed a Registration Statement on Form S-3 with the Securities and Exchange Commission (“SEC”) that will remove the restriction and permit the Company to sell the shares. The Company plans to fund future working capital requirements through the orderly sale of its shares in Navidea common stock and from potential future consideration due to the Company pursuant to the sublicense agreement.

Operating Activities

Net cash used for operating activities was $621,062 for the nine months ended September 30, 2012 compared to $2,067,243 for the nine months ended September 30, 2011. Net cash used for operating activities for the nine months ended September 30, 2012 reflects our curtailment of operations pending additional funding, the reduction in accrued interest expense associated with the debt reduction agreements signed in the fourth quarter of 2011 and the receipt of $675,000 from Navidea Biopharmaceuticals related to our Altropane product.

 

18

Table of Contents

Investing Activities

No cash was provided by investing activities for the nine months ended September 30, 2012. Cash provided by investing activities was $114,858 for the nine months ended September 30, 2011.

Financing Activities

Financing activities provided cash of $510,000 for the nine months ended September 30, 2012 compared to $1,940,000 for the nine months ended September 30, 2011. Cash provided by financing activities for the nine months ended September 30, 2012 and 2011 reflects the proceeds from the issuance of demand notes payable issued to Robert Gipson. All notes bear interest at the rate of 7% per annum.

During the nine months ended September 30, 2012, we used the $500,000 received from the option agreement with Navidea and the $175,000 received from the sublicense agreement with Navidea to cover a portion of our operating expenses. This allowed us to reduce our borrowing from our lead investor. In the past we had obtained all of our funding from Robert Gipson. In the event that Mr. Gipson cannot provide future funding or we cannot obtain any additional funding from other sources, we may need to cease operations or reduce, cease or delay research and development programs and/or adjust our current business plan and in any such event we may not be able to continue as a going concern.

To date, we have dedicated most of our financial resources to the research and development of our product candidates, general and administrative expenses (including costs related to obtaining and protecting patents). Since inception, we have primarily satisfied our working capital requirements from the sale of our securities through private placements. These private placements have included the sale and issuance of preferred stock, common stock, promissory notes and convertible debentures.

Our future working capital requirements have been reduced substantially due to the terms of the sublicense agreement with Navidea. Per the agreement, Navidea will use its best commercial efforts to develop and launch Altropane in accordance with an agreed to development plan for the product. Navidea will be responsible for conducting and funding all future development, regulatory filings, manufacturing and global commercialization of Altropane. The Company will have no further cost obligations related to Altropane. Our future working capital requirements will be determined by our ability to control certain necessary expenditures in connection with operating as a public company.

Our major source of future working capital will be earned as Navidea attains certain milestones. The sublicense agreement provides for contingent milestone payments to the Company of up to $2.9 million and the issuance of up to an additional 1.15 million shares of Navidea common stock. Milestone payments of $2.5 million and the issuance of 550,000 shares of Navidea common stock will occur at the time of product registration. The Company will be issued an additional 400,000 shares of Navidea common stock when certain cumulative net sales of the approved product are achieved. In addition, the license terms anticipate royalties on yearly net sales of the approved product which are consistent with industry-standard terms and certain license extension fees, payable in cash and shares of common stock, in the event certain milestones are not met.

In order to continue as a going concern, we will need to raise additional capital through one or more of the following: a debt financing, an equity offering, or a collaboration, merger, acquisition or other transaction with one or more pharmaceutical or biotechnology companies. We are currently engaged in fundraising efforts. There can be no assurance that we will be successful in our fundraising efforts or that additional funds will be available on acceptable terms, if at all. We also cannot be sure that we will be able to obtain additional credit from, or effect additional sales of debt or equity securities to certain of our existing investors. If we are unable to raise additional or sufficient capital or if we violate a debt covenant or default under the March 2008 Amended Purchase Agreement or the June 2008 Purchase Agreement (described below) we may need to cease operations or reduce, cease or delay one or more of our research or development programs and/or adjust our current business plan and in any such event may not be able to continue as a going concern.

Item 3 — Quantitative and Qualitative Disclosures about Market Risk

As a “smaller reporting company” as defined by Item 10 of Regulation S-K, we are not required to provide this information.

Item 4 — Controls and Procedures

Our management evaluated the effectiveness of our disclosure controls and procedures as of September 30, 2012. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of September 30, 2012, our chief executive officer and chief financial officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.

 

19

Table of Contents

Part II — OTHER INFORMATION

Item 1 — Legal Proceedings

On March 13, 2012 the Company received notice that Children’s Hospital Boston and Children’s Medical Center Corporation had filed a lawsuit in Middlesex Superior Court, Middlesex County, Massachusetts seeking to recover amounts alleged to be owed by the Company to the plaintiffs totaling $642,906. The Company estimates that total amounts claimed in the lawsuit are slightly higher than the actual amounts owed and will pursue all legal remedies available to it to defend this claim.

On May 2, 2012 the Company received notice that Biostorage Technologies, Inc. had filed a lawsuit in Marion Superior/Circuit Court, Marion County, Indiana seeking to recover amounts alleged to be owed by the Company to the plaintiffs totaling $119,363. The Company believes that the total amounts claimed in the Biostorage lawsuit are significantly overstated. The Company intends to pursue all available legal and equitable remedies to defend this claim.

The disclosure contained under the heading “Contingencies” in Note 9 to the condensed consolidated financial statements included in Part I, Item 1 hereof is incorporated herein by reference.

Statements contained or incorporated by reference in this Quarterly Report on Form 10-Q that are not based on historical fact are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Exchange Act. These forward-looking statements regarding future events and our future results are based on current expectations, estimates, forecasts, and projections, and the beliefs and assumptions of our management including, without limitation, our expectations regarding our product candidates, including the success and timing of our preclinical, clinical and development programs, the submission of regulatory filings and proposed partnering arrangements, the outcome of any litigation, collaboration, merger, acquisition and fund raising efforts, results of operations, selling, general and administrative expenses, research and development expenses and the sufficiency of our cash for future operations. Forward-looking statements may be identified by the use of forward-looking terminology such as “may,” “could,” “will,” “expect,” “estimate,” “anticipate,” “continue,” or similar terms, variations of such terms or the negative of those terms.

We cannot assure investors that our assumptions and expectations will prove to have been correct. Important factors could cause our actual results to differ materially from those indicated or implied by forward-looking statements. Such factors that could cause or contribute to such differences include those factors discussed below. We undertake no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Item 6 — Exhibits

 

  31.1*   Certification of the Chief Executive Officer pursuant to Section 1350 of Title 18, United States Code, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
  31.2*   Certification of the Chief Financial Officer pursuant to Section 1350 of Title 18, United States Code, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
  32.1*   Certification of the Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
  32.2*   Certification of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS**   XBRL Instance Document
101.SCH**   XBRL Taxonomy Extension Schema Document
101.CAL**   XBRL Taxonomy Extension Calculation Linkbase Document
101.LAB**   XBRL Taxonomy Extension Label Linkbase Document
101.PRE**   XBRL Taxonomy Presentation Linkbase Document
101.DEF**   XBRL Taxonomy Definition Linkbase Document

 

* Filed herewith.
** In accordance with Rule 406T of Regulation S-T, the XBRL related information in Exhibit 101 to this Quarterly Report on Form 10-Q shall not be deemed to be “filed” for purposed of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

 

20

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

    ALSERES PHARMACEUTICALS, INC
(Registrant)
DATE: November 14, 2012    

/s/ P ETER G. S AVAS

    Peter G. Savas
    Chief Executive Officer (Principal Executive Officer)
DATE: November 14, 2012    

/s/ K ENNETH L. R ICE , J R .

    Kenneth L. Rice, Jr.
    Executive Vice President Finance and Administration And Chief Financial Officer (Principal Financial and Accounting Officer)

 

21

Alseres Pharmaceuticals (CE) (USOTC:ALSE)
Historical Stock Chart
From Nov 2024 to Dec 2024 Click Here for more Alseres Pharmaceuticals (CE) Charts.
Alseres Pharmaceuticals (CE) (USOTC:ALSE)
Historical Stock Chart
From Dec 2023 to Dec 2024 Click Here for more Alseres Pharmaceuticals (CE) Charts.